These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24728441)

  • 1. [Liraglutide reduces biomarkers and vascular risk in patients with diabetes mellitus type 2].
    García de Lucas MD; Olalla J; Sempere M
    Rev Med Chil; 2013 Dec; 141(12):1602-4. PubMed ID: 24728441
    [No Abstract]   [Full Text] [Related]  

  • 2. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrating incretin-based therapy into type 2 diabetes management.
    Brunton SA
    J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
    [No Abstract]   [Full Text] [Related]  

  • 4. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 analogues for type 2 diabetes.
    Wilding JP; Hardy K
    BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
    [No Abstract]   [Full Text] [Related]  

  • 8. NICE approves liraglutide for diabetic patients not achieving glucose control.
    Mayor S
    BMJ; 2010 Sep; 341():c5062. PubMed ID: 20843934
    [No Abstract]   [Full Text] [Related]  

  • 9. Late and severe acute necrotizing pancreatitis in a patient with liraglutide.
    Bourezane H; Kastler B; Kantelip JP
    Therapie; 2012; 67(6):539-43. PubMed ID: 23249582
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus.
    Okada K; Kotani K; Yagyu H; Ando A; Osuga J; Ishibashi S
    Endocrine; 2014 Dec; 47(3):962-4. PubMed ID: 24696097
    [No Abstract]   [Full Text] [Related]  

  • 11. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
    Parks M; Rosebraugh C
    N Engl J Med; 2010 Mar; 362(9):774-7. PubMed ID: 20164475
    [No Abstract]   [Full Text] [Related]  

  • 12. Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.
    García de Lucas MD; Olalla Sierra J; Piña Fernández J
    Diabetes Metab; 2015 Feb; 41(1):102-3. PubMed ID: 25455831
    [No Abstract]   [Full Text] [Related]  

  • 13. [Liraglutide in the treatment of diabetes type 2].
    Novak B; Metelko Z
    Lijec Vjesn; 2011; 133(7-8):269-76. PubMed ID: 22165195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.
    Kapitza C; Zdravkovic M; Hindsberger C; Flint A
    Adv Ther; 2011 Aug; 28(8):650-60. PubMed ID: 21792552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?
    Besemer F; Verschoor AJ; Diamant M; Hoogma RP
    J Diabetes Complications; 2012; 26(5):458-9. PubMed ID: 22727533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dulaglutide and liraglutide compared].
    Bruhn C
    Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
    [No Abstract]   [Full Text] [Related]  

  • 18. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 20. Liraglutide for type 2 diabetes?
    Drug Ther Bull; 2010 May; 48(5):50-3. PubMed ID: 20447980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.